Cargando…

Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level

To evaluate clinical values of clinicopathologic and (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jae-Hoon, Kang, Jeonghyun, Baik, Seung Hyuk, Lee, Kang Young, Lim, Beom Jin, Jeon, Tae Joo, Ryu, Young Hoon, Sohn, Seung-Kook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706250/
https://www.ncbi.nlm.nih.gov/pubmed/26735530
http://dx.doi.org/10.1097/MD.0000000000002236
_version_ 1782409137662984192
author Lee, Jae-Hoon
Kang, Jeonghyun
Baik, Seung Hyuk
Lee, Kang Young
Lim, Beom Jin
Jeon, Tae Joo
Ryu, Young Hoon
Sohn, Seung-Kook
author_facet Lee, Jae-Hoon
Kang, Jeonghyun
Baik, Seung Hyuk
Lee, Kang Young
Lim, Beom Jin
Jeon, Tae Joo
Ryu, Young Hoon
Sohn, Seung-Kook
author_sort Lee, Jae-Hoon
collection PubMed
description To evaluate clinical values of clinicopathologic and (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate their variability depending on C-reactive protein (CRP) levels. In total, 179 CRC patients who underwent PET/CT scans before curative resection and KRAS mutation evaluation following surgery were enrolled. Maximum standardized uptake value (SUV(max)), peak standardized uptake value (SUV(peak)), metabolic tumor volume, and total lesion glycolysis were determined semiquantitatively. Associations between clinicopathologic and PET/CT-related parameters and KRAS expression were analyzed. Elevated CRP (>6.0 mg/L; n = 47) was associated with higher primary tumor size, higher SUV(max), SUV(peak), metabolic tumor volume, and total lesion glycolysis, compared with those for the group with a CRP lower than that the cutoff value (<6.0 mg/L; n = 132). Interestingly, the CRC patients (having CRP < 6.0 mg/L) with KRAS mutations had significantly higher (P < 0.05) SUV(max) and SUV(peak) values than the patients expressing wild-type KRAS mutations. Multivariate analysis revealed SUV(max) and SUV(peak) to be significantly associated with KRAS mutations (odds ratio = 3.3, P = 0.005, and odds ratio = 3.9, P = 0.004), together with histologic grade and lymph node metastasis. (18)F-FDG uptake was significantly higher in CRC patients with KRAS mutations and with normal CRP levels. A severe local inflammation with raised CRP levels, however, might affect accurate (18)F-FDG quantification in CRC tumors. Positron emission tomography/computed tomography-related parameters could supplement genomic analysis to determine KRAS expression in CRC; however, care should be exercised to guarantee proper patient selection.
format Online
Article
Text
id pubmed-4706250
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-47062502016-01-19 Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level Lee, Jae-Hoon Kang, Jeonghyun Baik, Seung Hyuk Lee, Kang Young Lim, Beom Jin Jeon, Tae Joo Ryu, Young Hoon Sohn, Seung-Kook Medicine (Baltimore) 5307 To evaluate clinical values of clinicopathologic and (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT)-related parameters for prediction of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in colorectal cancer (CRC) and to investigate their variability depending on C-reactive protein (CRP) levels. In total, 179 CRC patients who underwent PET/CT scans before curative resection and KRAS mutation evaluation following surgery were enrolled. Maximum standardized uptake value (SUV(max)), peak standardized uptake value (SUV(peak)), metabolic tumor volume, and total lesion glycolysis were determined semiquantitatively. Associations between clinicopathologic and PET/CT-related parameters and KRAS expression were analyzed. Elevated CRP (>6.0 mg/L; n = 47) was associated with higher primary tumor size, higher SUV(max), SUV(peak), metabolic tumor volume, and total lesion glycolysis, compared with those for the group with a CRP lower than that the cutoff value (<6.0 mg/L; n = 132). Interestingly, the CRC patients (having CRP < 6.0 mg/L) with KRAS mutations had significantly higher (P < 0.05) SUV(max) and SUV(peak) values than the patients expressing wild-type KRAS mutations. Multivariate analysis revealed SUV(max) and SUV(peak) to be significantly associated with KRAS mutations (odds ratio = 3.3, P = 0.005, and odds ratio = 3.9, P = 0.004), together with histologic grade and lymph node metastasis. (18)F-FDG uptake was significantly higher in CRC patients with KRAS mutations and with normal CRP levels. A severe local inflammation with raised CRP levels, however, might affect accurate (18)F-FDG quantification in CRC tumors. Positron emission tomography/computed tomography-related parameters could supplement genomic analysis to determine KRAS expression in CRC; however, care should be exercised to guarantee proper patient selection. Wolters Kluwer Health 2016-01-08 /pmc/articles/PMC4706250/ /pubmed/26735530 http://dx.doi.org/10.1097/MD.0000000000002236 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle 5307
Lee, Jae-Hoon
Kang, Jeonghyun
Baik, Seung Hyuk
Lee, Kang Young
Lim, Beom Jin
Jeon, Tae Joo
Ryu, Young Hoon
Sohn, Seung-Kook
Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level
title Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level
title_full Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level
title_fullStr Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level
title_full_unstemmed Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level
title_short Relationship Between (18)F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level
title_sort relationship between (18)f-fluorodeoxyglucose uptake and v-ki-ras2 kirsten rat sarcoma viral oncogene homolog mutation in colorectal cancer patients: variability depending on c-reactive protein level
topic 5307
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706250/
https://www.ncbi.nlm.nih.gov/pubmed/26735530
http://dx.doi.org/10.1097/MD.0000000000002236
work_keys_str_mv AT leejaehoon relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel
AT kangjeonghyun relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel
AT baikseunghyuk relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel
AT leekangyoung relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel
AT limbeomjin relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel
AT jeontaejoo relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel
AT ryuyounghoon relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel
AT sohnseungkook relationshipbetween18ffluorodeoxyglucoseuptakeandvkiras2kirstenratsarcomaviraloncogenehomologmutationincolorectalcancerpatientsvariabilitydependingoncreactiveproteinlevel